185 related articles for article (PubMed ID: 26810130)
1. Low Rates of Adoption and Implementation of Rapid HIV Testing in Substance Use Disorder Treatment Programs.
Frimpong JA; D'Aunno T; Helleringer S; Metsch LR
J Subst Abuse Treat; 2016 Apr; 63():46-53. PubMed ID: 26810130
[TBL] [Abstract][Full Text] [Related]
2. HIV testing in the nation's opioid treatment programs, 2005-2011: the role of state regulations.
D'Aunno T; Pollack HA; Jiang L; Metsch LR; Friedmann PD
Health Serv Res; 2014 Feb; 49(1):230-48. PubMed ID: 23855724
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and current clinical practices of opioid treatment programs in the United States.
Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
[TBL] [Abstract][Full Text] [Related]
4. Medicaid Expansion and Availability of Opioid Medications in the Specialty Substance Use Disorder Treatment System.
Abraham AJ; Yarbrough CR; Harris SJ; Adams GB; Andrews CM
Psychiatr Serv; 2021 Feb; 72(2):148-155. PubMed ID: 33267651
[TBL] [Abstract][Full Text] [Related]
5. Spillover effects of HIV testing policies: changes in HIV testing guidelines and HCV testing practices in drug treatment programs in the United States.
Frimpong JA; D'Aunno T; Helleringer S; Metsch LR
BMC Public Health; 2016 Jul; 16():666. PubMed ID: 27473519
[TBL] [Abstract][Full Text] [Related]
6. Viral Hepatitis and Human Immunodeficiency Virus Testing and Linkage to Care for Individuals Enrolled in an Opioid Treatment Program.
Rowan SE; Kamis KF; Beum R; Bryan K; Gawenus L; Colon Sanchez D; Hurley H
J Infect Dis; 2020 Sep; 222(Suppl 5):S384-S391. PubMed ID: 32877565
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C testing in substance use disorder treatment: the role of program managers in adoption of testing services.
Frimpong JA; D'Aunno T
Subst Abuse Treat Prev Policy; 2016 Apr; 11():13. PubMed ID: 27036115
[TBL] [Abstract][Full Text] [Related]
8. A study protocol for Project I-Test: a cluster randomized controlled trial of a practice coaching intervention to increase HIV testing in substance use treatment programs.
Frimpong JA; Parish CL; Feaster DJ; Gooden LK; Nelson MC; Matheson T; Siegel K; Haynes L; Linas BP; Assoumou SA; Tross S; Kyle T; Liguori TK; Toussaint O; Annane D; Metsch LR
Trials; 2023 Sep; 24(1):609. PubMed ID: 37749635
[TBL] [Abstract][Full Text] [Related]
9. Tailoring services in opioid treatment programs for patients involved in America's criminal justice system: national associations and variation by state and Medicaid expansion status.
Pro G; Montgomery BEE; Zaller N
Subst Abuse Treat Prev Policy; 2021 Jun; 16(1):50. PubMed ID: 34147098
[TBL] [Abstract][Full Text] [Related]
10. Opioid treatment programs in the Clinical Trials Network: representativeness and buprenorphine adoption.
Ducharme LJ; Roman PM
J Subst Abuse Treat; 2009 Jul; 37(1):90-4. PubMed ID: 19004597
[TBL] [Abstract][Full Text] [Related]
11. Provision of onsite HIV Services in Substance Use Disorder Treatment Programs: A Longitudinal Analysis.
Aletraris L; Roman PM
J Subst Abuse Treat; 2015 Oct; 57():1-8. PubMed ID: 25934459
[TBL] [Abstract][Full Text] [Related]
12. Determinants of the availability of hepatitis C testing services in opioid treatment programs: results from a national study.
Frimpong JA; D'Aunno T; Jiang L
Am J Public Health; 2014 Jun; 104(6):e75-82. PubMed ID: 24825236
[TBL] [Abstract][Full Text] [Related]
13. Introduction of Medicare coverage in opioid treatment programs: Findings from the first three years.
Abraham AJ; Harris SJ; Yarbrough CR
J Subst Use Addict Treat; 2024 Mar; 158():209247. PubMed ID: 38072386
[TBL] [Abstract][Full Text] [Related]
14. On-site bundled rapid HIV/HCV testing in substance use disorder treatment programs: study protocol for a hybrid design randomized controlled trial.
Frimpong JA; D'Aunno T; Perlman DC; Strauss SM; Mallow A; Hernandez D; Schackman BR; Feaster DJ; Metsch LR
Trials; 2016 Mar; 17(1):117. PubMed ID: 26936623
[TBL] [Abstract][Full Text] [Related]
15. On-site HIV testing in residential drug treatment units: results of a nationwide survey.
Strauss SM; Des Jarlais DC; Astone J; Vassilev ZP
Public Health Rep; 2003; 118(1):37-43. PubMed ID: 12604763
[TBL] [Abstract][Full Text] [Related]
16. Top manager effects on buprenorphine adoption in outpatient substance abuse treatment programs.
Friedmann PD; Jiang L; Alexander JA
J Behav Health Serv Res; 2010 Jul; 37(3):322-37. PubMed ID: 19296223
[TBL] [Abstract][Full Text] [Related]
17. National trends in testing for hepatitis C virus in licensed opioid treatment programs: Differences by facility ownership and state medicaid expansion status.
Pro G; Tompkins DA; Azari S; Zaller N
Drug Alcohol Depend; 2021 Nov; 228():109092. PubMed ID: 34571287
[TBL] [Abstract][Full Text] [Related]
18. Association of random and observed urine drug screening with long-term retention in opioid treatment programs.
Michener PS; Knee A; Wilson D; Boama-Nyarko E; Friedmann PD
Drug Alcohol Depend; 2024 Feb; 255():111067. PubMed ID: 38183832
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
